Previous 10 | Next 10 |
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22; scientific advis...
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on September 27, 2021,...
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added ENGLEWOOD, CO / ACCESSWIRE / September 9, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company fo...
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during ...
Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification ...
Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) traded at a new 52-week low today of $3.87. This new low was reached on approximately average trading volume as 1.1 million shares traded hands, while the average 30-day volume is approximately 1.2 million shares. Aytu BioPharma Inc is a specia...
EyeGate Pharmaceuticals EYEG +127% names Brian Strem CEO, proposes $7M Bayon dealObsEva SA OBSV +28%, Organon ink ebopiprant licensing deal for preterm laborOrbsat Corp. (OSAT) +27%.MOGU Inc. (MOGU) +21% announces entry into Definitive Agreements to increase ownershi...
ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the...
Aytu BioPharma Inc. (NASDAQ:AYTU) traded at a new 52-week low today of $4.02. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. Aytu BioPharma Inc. (NASDAQ:AYTU) has potential upside of 266.8% based on a curr...
Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) traded at a new 52-week low today of $4.23. This new low was reached on approximately average trading volume as 1.1 million shares traded hands, while the average 30-day volume is approximately 1.5 million shares. Aytu BioPharma Inc is a specia...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...